ArticleScientific reports2025
The relationship between urinary glyphosate and all-cause and specific-cause mortality: a prospective study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Why internists should be concerned about glyphosate.Internal and emergency medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Glyphosate (GLY) is a well-known herbicide with significant applications in both agriculture and non-agriculture. However, GLY overuse in recent years has resulted in detection of GLY residues in many crops, endangering human health and food safety. Our aim is to investigate the relationship between urinary GLY and mortality, as well as its influencing factors. The National Health and Nutrition Examination Survey (NHANES) data from 4740 American adults were examined. Fitted smooth curves, generalized summation models, and multiple logistic regression models were used to investigate the relationship between urinary GLY and mortality. To investigate potential regulatory elements between the two effects, perform subgroup analysis. During a median follow-up of 4.03 years, there were a total of 238 all-cause deaths, 75 cardiovascular disease (CVD) deaths and 52 cancer deaths. The urinary GLY is positively correlated with all-cause mortality. Each 1 ng/ml increase in urinary GLY was associated with a 40% increased risk of all-cause mortality (Hazard ratio (HR) 1.40, 95% confidence interval (CI) 1.09-1.80), and an 50% increased risk of all-cause mortality in High group compared with Low group (HR 1.50, 95% CI 1.05-2.14). In subgroup analysis, the association between urinary GLY and all-cause mortality was significantly modified by gender (P for interaction = 0.03), and the association between urinary GLY and cancer mortality was significantly modified by hypertension (P for interaction = 0.022). Higher urinary GLY seems to be associated with more all-cause death, and gender may affect this association. Furthermore, urine GLY may have a higher effect on cancer mortality in people without hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.